Monday, November 30, 2015
Merck, of Darmstadt, Germany, and Pfizer have announced that the FDA has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.
Merck, a Germany-based science and technology company, has been named one of the top 20 employers in the biopharmaceutical industry by Science magazine, a peer-reviewed international scientific publication. Merck ranked 17th among biotechnology and pharmaceutical companies worldwide. This is the second year in a row that Merck has been named to the top employer list, improving from its position of number 20 in 2014.
Darmstadt, Germany-based Merck has re-launched its visual identity. The fundamental revision of the visual appearance—as well as the introduction of new logos for its U.S. businesses EMD Serono, EMD Millipore and EMD Performance Materials—reflects a transformation into a global science and technology company.
Researchers funded by the NIH and the Foundation for the NIH (FNIH) have expanded a recently launched online library, called a knowledge portal, which allows open-access searching of human genetic and clinical information on type 2 diabetes. Individual data will remain confidential. The portal includes information from several major international networks, collected from decades of research.